Lancet:早期乳腺癌术后1周26Gy放疗方案效果评估

2020-04-29 MedSci原创 MedSci原创

对于早期乳腺癌术后接受局部辅助放疗患者,采用1周以上,5次,总计26Gy的放疗方案对疾病的控制效果与传统的3周以上,15次,总计40Gy放疗方案相当

近日研究人员公布了FAST-Forward试验的5年结果,该研究考察了早期乳腺癌患者接受5-fraction方案的效果。
 
FAST-Forward是在英国97家医院开展,为多中心、第三阶段、随机、非劣效性试验。年龄在18岁以上的乳腺浸润性癌患者(pT1-3,pN0-1,M0)接受保乳手术或乳腺切除术,随机分为3周以上,共15次,总计40 Gy 的放疗、1周以上,共5次,总计27 Gy 放疗或1周以上,共5次,总计26 Gy 放疗。研究的主要终点是同侧乳腺肿瘤复发。
 
4096名患者参与,其中1361名接受40Gy治疗,1367名患者接受27Gy治疗,1368名患者接受26Gy治疗。在71.5个月的中位随访中,79例患者(40 Gy组31例,27 Gy组27例,26 Gy组21例)发生了主要终点事件,40Gy组与27 Gy 组相比,复发风险为0.86,与26 Gy组相比较为0.67。与40 Gy组相比,27Gy和26 Gy组的风险绝对差异分别为-0.3%和-0.7%。在5年时, 40Gy组98例(9.9%)患者、27Gy组155例患者(15.4%)以及26Gy组121例(11.9%)患者在乳房或胸壁评估中存在正常的组织效应。对临床医生的评估中,与40Gy组相比,27Gy组对的临床优势比为1.55,26Gy组为1.12。患者和摄影评估显示27 Gy 与40 Gy相比,对正常组织影响风险较高,但26 Gy组的正常组织影响风险不高。
 
研究认为,对于早期乳腺癌术后接受局部辅助放疗患者,采用1周以上,5次,总计26Gy的放疗方案对疾病的控制效果与传统的3周以上,15次,总计40Gy放疗方案相当。
 
原始出处:
 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1830613, encodeId=510f183061318, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 07 07:53:45 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890938, encodeId=ca48189093855, content=<a href='/topic/show?id=84505e5207c' target=_blank style='color:#2F92EE;'>#效果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57520, encryptionId=84505e5207c, topicName=效果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun May 03 19:53:45 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382358, encodeId=cff5382358c7, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Thu Apr 30 12:32:26 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033755, encodeId=6d4c1033e55dc, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Apr 29 22:53:45 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047051, encodeId=d72f104e05150, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 29 22:53:45 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382332, encodeId=ab9638233253, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Wed Apr 29 21:41:06 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-10-07 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1830613, encodeId=510f183061318, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 07 07:53:45 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890938, encodeId=ca48189093855, content=<a href='/topic/show?id=84505e5207c' target=_blank style='color:#2F92EE;'>#效果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57520, encryptionId=84505e5207c, topicName=效果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun May 03 19:53:45 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382358, encodeId=cff5382358c7, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Thu Apr 30 12:32:26 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033755, encodeId=6d4c1033e55dc, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Apr 29 22:53:45 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047051, encodeId=d72f104e05150, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 29 22:53:45 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382332, encodeId=ab9638233253, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Wed Apr 29 21:41:06 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1830613, encodeId=510f183061318, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 07 07:53:45 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890938, encodeId=ca48189093855, content=<a href='/topic/show?id=84505e5207c' target=_blank style='color:#2F92EE;'>#效果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57520, encryptionId=84505e5207c, topicName=效果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun May 03 19:53:45 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382358, encodeId=cff5382358c7, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Thu Apr 30 12:32:26 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033755, encodeId=6d4c1033e55dc, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Apr 29 22:53:45 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047051, encodeId=d72f104e05150, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 29 22:53:45 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382332, encodeId=ab9638233253, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Wed Apr 29 21:41:06 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-04-30 946207329

    感谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1830613, encodeId=510f183061318, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 07 07:53:45 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890938, encodeId=ca48189093855, content=<a href='/topic/show?id=84505e5207c' target=_blank style='color:#2F92EE;'>#效果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57520, encryptionId=84505e5207c, topicName=效果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun May 03 19:53:45 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382358, encodeId=cff5382358c7, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Thu Apr 30 12:32:26 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033755, encodeId=6d4c1033e55dc, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Apr 29 22:53:45 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047051, encodeId=d72f104e05150, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 29 22:53:45 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382332, encodeId=ab9638233253, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Wed Apr 29 21:41:06 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-04-29 goodbing

    顶刊就是不一样,质量很高,内容精彩!学到很多

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1830613, encodeId=510f183061318, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 07 07:53:45 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890938, encodeId=ca48189093855, content=<a href='/topic/show?id=84505e5207c' target=_blank style='color:#2F92EE;'>#效果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57520, encryptionId=84505e5207c, topicName=效果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun May 03 19:53:45 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382358, encodeId=cff5382358c7, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Thu Apr 30 12:32:26 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033755, encodeId=6d4c1033e55dc, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Apr 29 22:53:45 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047051, encodeId=d72f104e05150, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 29 22:53:45 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382332, encodeId=ab9638233253, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Wed Apr 29 21:41:06 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-04-29 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1830613, encodeId=510f183061318, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 07 07:53:45 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890938, encodeId=ca48189093855, content=<a href='/topic/show?id=84505e5207c' target=_blank style='color:#2F92EE;'>#效果评估#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57520, encryptionId=84505e5207c, topicName=效果评估)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun May 03 19:53:45 CST 2020, time=2020-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382358, encodeId=cff5382358c7, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9ca45017967, createdName=946207329, createdTime=Thu Apr 30 12:32:26 CST 2020, time=2020-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033755, encodeId=6d4c1033e55dc, content=顶刊就是不一样,质量很高,内容精彩!学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=goodbing, createdTime=Wed Apr 29 22:53:45 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047051, encodeId=d72f104e05150, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Apr 29 22:53:45 CST 2020, time=2020-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382332, encodeId=ab9638233253, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d0d5314558, createdName=1902498648_44512810, createdTime=Wed Apr 29 21:41:06 CST 2020, time=2020-04-29, status=1, ipAttribution=)]
    2020-04-29 1902498648_44512810

    0

相关资讯

Lancet Oncol:放疗是否会影响导管原位癌患者保乳手术后的生活质量?

侵袭性乳腺癌治疗对健康相关生活质量(HRQOL)的影响已被证实,但乳腺导管原位癌治疗对HRQOL影响的证据缺乏。BIG 3-07/TROG 07 .01 是一项国际随机对照3期研究,拟评估瘤床增量和不

乳腺癌规范化治疗更上一层楼!李俊杰教授详细解读乳腺癌新辅助诊疗新标准

对于乳腺癌的新辅助治疗而言,既往在临床工作中发现,新辅助治疗作为一种有效的治疗手段,其需要较为复杂的治疗决策和较高的执行能力。具体由谁来做、如何做以及在治疗过程中如何进行精细化管理和调整显得尤为重要。

J Immunol Res:人类免疫系统可增加乳腺癌诱导的成骨细胞骨质增生而不影响正常的骨质增生

骨转移在许多常见癌症如乳腺癌、前列腺癌和肺癌等常见癌症中普遍存在,治疗骨转移的新疗法是需要的。人类免疫系统移植模型被用于免疫肿瘤学(IO)研究中,用于皮下肿瘤细胞或患者衍生的异种移植植入模拟原发性肿瘤

抗PVRIG抗体COM701在早期研究中显示出抗肿瘤活性

Compugen制药公司今日宣布,将在2020年美国癌症研究协会(AACR)年会上提交的数据表明,在I期研究中,实验性抗PVRIG抗体COM701表现出高疾病控制率。

Int J Mol Sci:骨骼微环境中TGF-β信号对癌细胞和癌干细胞的影响

转化生长因子-β(TGF-β)在骨转移形成中起着关键作用;我们假设TGF-β可能参与诱导骨微环境(micro-E)中的肿瘤干细胞(CSCs),这可能是化疗抗药性的原因。

AACR 2020:Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高

高危HER2阴性乳癌的新辅助治疗疗效一直有待临床提升,此前PDL1单抗durva+奥拉帕尼在BRCA突变HER2阴性乳癌中,疾病控制率80%。这项研究名为MEDIOLA的II期临床试验,探索了PD-L